Americas Demand Drove a 1Q Beat, While China Business Headwinds Still Need to Clear

Overview

Sysmex announced its FY2026 first-quarter results on August 7, 2026. Both sales and operating profit exceeded expectations, with operating profit reaching ¥14.8 billion, about 52% above market consensus. The beat was mainly due to normalization of the post-pandemic extended revenue recognition cycle for equipment orders in the Americas, accelerating recognition of the FY2025 order backlog. Sales in EMEA and Asia-Pacific were also relatively solid, with a weaker yen providing additional support. Based on this, management raised its first-half and FY2026 operating profit guidance, but the impact of China's testing fee policy and changes in product mix on margins still need to be monitored.

Core views

First, demand for hematology equipment and revenue recognition in the Americas were strong, validating growth momentum in the overseas business. Second, sales growth was accompanied by a higher share of equipment revenue in the Americas, and product mix deterioration weighed on gross margin, meaning the revenue beat did not fully translate into proportional margin improvement. Third, China's hematology business performed well, but the hemostasis business was below guidance, and the testing fee standardization policy is expected to have a more visible impact around the fourth quarter of FY2026. Fourth, the business portfolio review to be announced in the second quarter may raise market expectations for improvements in low-margin businesses. Fifth, the target price is below the current share price, indicating limited absolute return potential at the current valuation.

Analysis framework

The report conducts variance analysis by combining actual quarterly results, company guidance, market consensus, and JPMorgan forecasts, and breaks down sales performance, product mix, and foreign exchange impact by region and business line; valuation uses a method of multiplying FY2026 forecast EPS by a target P/E multiple, while comparing it with the company's historical valuation and valuations in Japan's medical technology sector.

Methodology notes

• earnings_analysisEarnings expectation gap analysis

  Compare actual results, company guidance, and market consensus

  Identify the sources of the first-quarter beat through sales, operating profit, margins, and regional business data, and assess their sustainability.

• segment_analysisRegional and business segment analysis

  Break down the growth contributions of hematology and hemostasis businesses across different regions

  Focus on sales growth in the Americas, EMEA, China, and Asia-Pacific, as well as the impact of changes in the equipment and reagent mix on gross margin.

• Valuation methodsP/E valuation method

  FY2026 forecast EPS multiplied by a 23x target P/E

  The target P/E is above the Japanese medical technology sector average of about 18x, but below the company's historical average of about 34x since 2013 excluding pandemic years; the report believes the company's high market share and overseas sales growth can support a certain valuation premium.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Sysmex (6869.T)

  The Japanese medical technology stock directly covered by the report

  Strengths

  High market share in hematology products and rapid overseas sales growth; normalization of the Americas order revenue recognition cycle; XR series expansion and growth in the European and U.S. hematology businesses can serve as earnings drivers.

  Weaknesses

  A rising share of equipment sales leads to a weaker product mix and weighs on gross margin; China's hemostasis business is below guidance; the target price is below the share price at the time of the report.

  Comparison

  The 23x target P/E is above the Japanese medical technology sector average of about 18x, but below the company's long-term historical average of about 34x.

  Risks

  China business may slow due to economic conditions, government policy, or the competitive environment; sales of the XR series and the hemostasis businesses in Europe, the U.S., and China may fall short of expectations; exchange rate changes may affect overseas revenue and profit.

Key data

• First-quarter sales¥130.7 billionUp 23.6% year over year, above JPMorgan's forecast of ¥116.6 billion and market consensus of ¥117.5 billion.
• First-quarter operating profit¥14.8 billionUp 39.5% year over year, above JPMorgan's forecast of ¥9.7 billion and market consensus of ¥9.6 billion.
• First-quarter operating margin11.3%Above JPMorgan's forecast of 8.3% and market consensus of 8.2%.
• First-quarter gross margin50.7%Increased hematology equipment sales in the Americas weakened the product mix, limiting gross margin performance.
• Americas hematology sales¥33.4 billionUp 40.7% year over year, significantly above expectations and the main source of this quarter's sales beat.
• FY2026 operating profit guidance¥60.0 billionManagement raised guidance by ¥2.0 billion from the previous forecast; JPMorgan's forecast is ¥59.6 billion, and market consensus is ¥62.2 billion.
• Target P/E23xAbove the Japanese medical technology sector level of about 18x, but below the company's historical average of about 34x after excluding pandemic years.
• Target price and current price¥1,600 / ¥1,652The target price corresponds to December 2026 and implies approximately 3.1% downside versus the August 7, 2026 closing price.

Impact & implications

The first-quarter earnings beat and guidance increase are likely to generate a somewhat positive near-term share price reaction and strengthen market confidence in growth in the Americas and European hematology businesses. If the second-quarter business portfolio review presents credible measures to improve low-margin businesses, or if the impact of China's testing fee policy gradually becomes clearer, valuation sentiment may recover further. However, the target price is already below the share price at the time of the report, and market consensus full-year operating profit remains above the company's new guidance, implying that the current price has already factored in some positive expectations.

Risks

• China's testing fee standardization policy may have a greater impact around the fourth quarter of FY2026, but the actual magnitude and timing remain uncertain.
• Deterioration in China's economy, government policies, or competitive environment may lead to further slowing of local business.
• Sales of XR series hematology equipment in the United States may be below expectations.
• Sales growth in the hemostasis businesses in the United States, Europe, and China may be below expectations.
• A higher share of equipment sales in the Americas may continue to cause an unfavorable product mix and weigh on gross margin.
• Fluctuations in the yen exchange rate may change the translated amount of overseas sales and operating profit.
• JPMorgan discloses that it has market-making, client, and potential investment banking relationships with Sysmex or related entities, and investors should pay attention to potential conflicts of interest.

What to watch

• The business portfolio review and measures to improve low-margin businesses to be announced together with second-quarter results.
• The sustainability of growth after normalization of the cycle from equipment orders to revenue recognition in the Americas.
• Sales performance and installed-base expansion of XR series hematology equipment in the United States.
• Sales growth rates of the hemostasis businesses in the United States and Europe.
• Divergence between China's hemostasis and hematology businesses.
• The implementation timing, scope, and profit impact of China's testing fee standardization policy.
• The subsequent impact of product mix changes on gross margin and operating margin.
• Whether FY2026 operating profit can meet or exceed the new guidance and market consensus.